Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Kappos

Calabresi

et al . Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779–1787.

Hauser

Bar-Or

Comi

et al . Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2016; 376: 221–234.

Montalban

Hauser

Kappos

et al . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2016; 376: 209–220.

Emery

Rigby

Tak

et al . Safety with ocrelizumab in rheumatoid arthritis: Results from the ocrelizumab phase III program. PLoS ONE 2014; 9: e87379.

Hauser

Waubant

Arnold

et al . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

Hawker

O’Connor

Freedman

et al . Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.

Alping

Frisell

Novakova

et al . Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; 79: 950–958.

Granqvist

Boremalm

Poorghobad

et al . Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. Epub ahead of print 8 January 2018. DOI: 10.1001/jamaneurol.2017.4011.

Spelman

Frisell

Piehl

et al . Comparative effectiveness of rituximab relative to IFN-beta or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler 2018; 24: 1087–1095.

10.

Bachelet

Hassler

Mbogning

et al . Occurrence of anti-drug antibodies against interferon-beta and natalizumab in multiple sclerosis: A collaborative cohort analysis. PLoS ONE 2016; 11: e0162752.

11.

Bar-Or

Calabresi

Arnold

et al . Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395–400.

12.

Dunn

Juto

Ryner

et al . Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler 2018; 24:1224–1233.

13.

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000RiskR.pdf

14.

Wadstrom

Frisell

Askling

et al . Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden. JAMA Intern Med 2017; 177: 1605–1612.

15.

Salzer

Svenningsson

Alping

et al . Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology 2016; 87: 2074–2081.

16.

Ladanie

Ioannidis

JPA

Stafford

et al . Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. Epub ahead of print 13 November 2017. DOI: 10.1016/j.jclinepi.2017.11.006.

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes

Abstract

Get full access to this article

References